AMAG Pharmaceuticals
1100 Winter Street
Waltham
Massachusetts
02451
United States
Tel: 617-498–3300
Fax: 617-499-3361
Website: http://www.amagpharma.com/
Email: contactus@amagpharma.com
About AMAG Pharmaceuticals
Founded in 1981, AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products.
AMAG currently markets a therapeutic intravenous iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) and an oral rinse for the management of oral mucositis in the United States. To learn more about our products, click here. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers.
Our iron oxide particles are composed of bioavailable iron that is easily absorbed by the body and incorporated into the body's iron stores. As a result, products using our core technology are well suited for use in intravenous iron replacement therapy.
374 articles about AMAG Pharmaceuticals
-
AMAG Pharmaceuticals Completes Sale of its Rights to Intrarosa® to Millicent Pharma for up to $125 Million
5/21/2020
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it has completed the sale of its rights to Intrarosa® (prasterone) to Millicent Pharma Limited, a global pharmaceutical company formed by the Millicent Pharma management team and The Carlyle Group in 2018 that specializes in women’s health and menopause-related conditions, for up to $125 million,
-
The restructuring is related to the planned divestiture of Intrarosa (prasterone) and Vyleesi (bremelanotide injection) and the impact of the COVID-19 pandemic.
-
AMAG Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate Update
5/11/2020
AMAG Pharmaceuticals, Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2020.
-
AMAG Pharmaceuticals Appoints Scott Myers as President and Chief Executive Officer
4/28/2020
AMAG Pharmaceuticals, Inc. announced that its Board of Directors has appointed Scott Myers as AMAG’s President and Chief Executive Officer, and member of the Board, effective immediately.
-
AMAG Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast on Monday, May 11, 2020
4/27/2020
AMAG Pharmaceuticals, Inc. announced that its first quarter 2020 financial results will be released on Monday, May 11, 2020 before the U.S. financial markets open.
-
AMAG Pharmaceuticals Provides COVID-19 Company Update
4/16/2020
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today provided an update regarding the potential impact of COVID-19 on the company. AMAG is committed to the health and safety of its employees, patients, healthcare providers, business partners and communities and is following the guidance from the Center for Disease Control (CDC) and Prevention and local public health authorities, including implementing a work from home policy for all employees. Al
-
AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateConference call scheduled for 8:00 a.m. EST today
3/4/2020
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2019.
-
AMAG Pharmaceuticals Announces Changes to Medical Development Organization
3/4/2020
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced changes to its medical development organization.
-
AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, March 4, 2020 at 8:00 a.m. ET
2/28/2020
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its fourth quarter and full year 2019 financial results will be released on Wednesday, March 4, 2020 before the U.S. financial markets open.
-
AMAG Pharmaceuticals to Participate in Upcoming Investor Conferences
2/14/2020
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will participate in the following investor conferences:
-
As is often the case at the beginning and end of the year, a number of companies announced layoffs. Other news is related to lawsuits and an overall positive story about cancer death rates. Here’s a look.
-
AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update
1/9/2020
AMAG Pharmaceuticals, Inc. announced the initiation of a leadership transition, the decision to divest Intrarosa and Vyleesi and financial updates
-
AMAG Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/3/2020
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time), in San Francisco, California.
-
AMAG Pharmaceuticals Awards Four Grants to Support Preterm Birth and Preeclampsia Research
12/18/2019
As part of the company’s ongoing support of research to reduce preterm birth and preeclampsia and associated complications, AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it has awarded four grants totaling nearly $300,000 to independent researchers in the field.
-
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
11/13/2019
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences
-
AMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provides Corporate Update
11/1/2019
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the third quarter ended September 30, 2019 and provided a business update.
-
Based on Failed Confirmatory Trial, FDA Adcom Recommends Pulling AMAG's Makena From the Market
10/30/2019
Makena has been approved to decrease preterm birth in pregnant women with a previous spontaneous preterm birth. -
AMAG Reports on FDA Advisory Committee Meeting for Makena® (Hydroxyprogesterone Caproate Injection)Company to Comment During Third Quarter Financial Results Conference Call on Friday, November 1, 2019, at 8:00 a.m. ET
10/29/2019
The advisory committee's recommendation, while not binding, will be considered by the FDA in making its decision.
-
AMAG Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss the Results of the Makena PROLONG Trial
10/29/2019
AMAG Pharmaceuticals, Inc. announced that NASDAQ has halted trading of the company’s common stock.
-
Clinical Catch-Up: October 21-25
10/28/2019
Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look.